Influence of age on the effectiveness of PCV2 vaccination in piglets with high levels of maternally derived antibodies

Haake, M.; Palzer, Andreas; Rist, Beate; Weissenbacher‐Lang, Christiane; Fachinger, Vicky; Eggen, A.; Ritzmann, M.; Eddicks, Matthias

doi:10.1016/j.vetmic.2013.11.012

Cited by 36 publications

(50 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Vaccination schedules at earlier ages with one single dose are rarely applied, since high levels of maternally derived antibodies (MDA) at the vaccination time may cause a lower humoral immune response (interference with the seroconversion) elicited by the vaccine [6, 11, 28, 29] and may eventually jeopardize the efficacy of vaccination [8, 30]. …”

Section: Discussionmentioning

confidence: 99%

Evaluation of natural porcine circovirus type 2 (PCV2) subclinical infection and seroconversion dynamics in piglets vaccinated at different ages

Oliver-Ferrando

Segalés

López-Soria

et al. 2016

Vet Res

View full text Add to dashboard Cite

This study aimed to determine the porcine circovirus type 2 (PCV2) serological and virological dynamics in piglets vaccinated at different ages in a PCV2 subclinical infection (PCV2-SI) scenario. Six hundred and forty-four 2 week-old healthy piglets were selected and distributed into four treatment groups: vaccination at 3, 6 or 10 weeks of age (3W-VAC, 6W-VAC and 10W-VAC groups, respectively) and unvaccinated pigs (NON-VAC group). Blood (n = 112 pigs) and oral fluid (OF) (n = 40 pens) samples were taken throughout the study to assess PCV2 load, humoral immunity and viral genotyping. Percentage of PCV2-DNA positive sera mainly raised by 10 weeks of age, being maximum at 14 weeks of age, and then started to decrease at 18 and 25 weeks of age. Specifically, PCV2 vaccination at 3 or 6 weeks of age yielded similar results, since they produced an earlier seroconversion and reduced, at different sampling points, the proportion of viremic animals in comparison to the unvaccinated group. In contrast, PCV2 vaccination at 10 weeks of age only achieved such reduction at 25 weeks of age; in this case, vaccination coincided with the increase of the percentage of viremic pigs in the population. Both serological techniques used in sera and OF offered similar results with a high and statistically significant correlation. In contrast, a higher percentage of PCV2 DNA positivity was detected in OF in comparison with sera. In conclusion, under the present study conditions, the optimal time for PCV2 piglet vaccination was at either 3 or 6 weeks of age.

show abstract

Section: Discussionmentioning

confidence: 99%

Evaluation of natural porcine circovirus type 2 (PCV2) subclinical infection and seroconversion dynamics in piglets vaccinated at different ages

Oliver-Ferrando

Segalés

López-Soria

et al. 2016

Vet Res

View full text Add to dashboard Cite

show abstract

“…Baculovirus-produced VLPs have been developed previously as agricultural vaccines including VLP vaccine against porcine circovirus type 2 (PCV2) [23, 24]. Expression of PCV2 ORF2 in insect cells resulted in VLPs that were structurally and antigenically similar to PCV2 capsids and were highly immunogenic [25].…”

Section: Discussionmentioning

confidence: 99%

Vaccination with virus-like particles containing H5 antigens from three H5N1 clades protects chickens from H5N1 and H5N8 influenza viruses

Kapczynski

Tumpey

Hidajat

et al. 2016

Vaccine

View full text Add to dashboard Cite

Highly pathogenic avian influenza (HPAI) viruses, especially H5N1 strains, represent a public health threat and cause widespread morbidity and mortality in domestic poultry. Recombinant virus-like particles (VLPs) represent a promising novel vaccine approach to control avian influenza including HPAI strains. Influenza VLPs contain viral hemagglutinin (HA), which can be expressed in cell culture within highly immunogenic VLPs that morphologically and antigenically resemble influenza virions, except VLPs are non-infectious. Here we describe a recombinant VLP containing HA proteins derived from three distinct clades of H5N1 viruses as an experimental, broadly protective H5 avian influenza vaccine. A baculovirus vector was configured to co-express the H5 genes from recent H5N1 HPAI isolates A/chicken/Germany/2014 (clade 2.3.4.4), A/chicken/West Java/Subang/29/2007 (clade 2.1.3) and A/chicken/Egypt/121/2012 (clade 2.2.1). Co-expression of these genes in Sf9 cells along with influenza neuraminidase (NA) and retrovirus gag genes resulted in production of triple-clade H555 VLPs that exhibited hemagglutination activity and morphologically resembled influenza virions. Vaccination of chickens with these VLPs resulted in induction of serum antibody responses and efficient protection against experimental challenges with three different viruses including the recent U.S. H5N8 HPAI isolate. We conclude that these novel triple-clade VLPs represent a feasible strategy for simultaneously evoking protective antibodies against multiple variants of H5 influenza virus.

show abstract

“…Blood samples were collected from 45 piglets per group at regular intervals (3, 6, 10, 14, 18, 22 week of age) and the sera were tested with ELISA for antibodies against PCV2 [25] and M. hyo (Swine HerdChek M. Hyo IDEXX). The blood samples collected at 18 and 22 weeks were tested by qPCR for PCV2 DNA.…”

Section: Methodsmentioning

confidence: 99%

“…For PCV2 an in-house ELISA of MSD Animal Health was used as previously described [25]. Titres in the PCV2 ELISA were expressed as the reciprocal of the serum dilution with a calculated extinction value of 50 % maximum extinction.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Field efficacy study of a novel ready-to-use vaccine against mycoplasma hyopneumoniae and porcine circovirus type 2 in a Greek farm

Tzika

Tassis

Koulialis³

et al. 2015

Porc Health Manag

View full text Add to dashboard Cite

BackgroundThe primary objective of this study was to assess the efficacy, under field conditions, of a novel ready-to use Mycoplasma hyopneumoniae (M hyo) and Porcine circovirus type 2 (PCV2) combination vaccine given to piglets as one vaccination (1-shot) at 3 weeks of age. The study was carried out according to a controlled, randomised, and blinded design in a Greek pig herd with clinical M. hyo and subclinical PCV2 infection. Moreover, based on serology at the time of vaccination, the average PCV2 titre was 9.15 log2 and represented the level of maternally derived antibodies (MDA). In total 602 healthy suckling piglets, originating from 4 weekly farrowing batches were allocated randomly, within litters, to one of two groups. The pigs in one group were vaccinated with the test product and the other pigs were injected with saline.ResultsVaccination significantly reduced lesions of craneo-ventral pulmonary consolidation in vaccinated group [expressed as lung lesion score (LLS)] (Mixed model ANOVA: p < 0.0001). The mean LLS was 17.1 in the controls and 10.6 in the treatment group, respectively. The average daily weight gain (ADWG) during the finishing (54 g better in the treatment group) and whole study period (34 g better in vaccinated animals) was significantly greater in vaccinated than control pigs. The vaccinated pigs had a significant reduction of PCV2 viraemia when compared with the controls.ConclusionsThe test product was considered effective in the face of average MDA, based on significantly reduced severity of LLS and PCV2 viral load, as well as improved ADWG in vaccinated versus control pigs.

show abstract

Influence of age on the effectiveness of PCV2 vaccination in piglets with high levels of maternally derived antibodies

Cited by 36 publications

References 20 publications

Evaluation of natural porcine circovirus type 2 (PCV2) subclinical infection and seroconversion dynamics in piglets vaccinated at different ages

Evaluation of natural porcine circovirus type 2 (PCV2) subclinical infection and seroconversion dynamics in piglets vaccinated at different ages

Vaccination with virus-like particles containing H5 antigens from three H5N1 clades protects chickens from H5N1 and H5N8 influenza viruses

Field efficacy study of a novel ready-to-use vaccine against mycoplasma hyopneumoniae and porcine circovirus type 2 in a Greek farm

Contact Info

Product

Resources

About